Avacincaptad Pegol Intravitreal

Avacincaptad Pegol Intravitreal is a prescription medication used for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD).

• Avacincaptad Pegol Intravitreal is available under the following different brand names: Izervay

Common side effects of Avacincaptad Pegol Intravitreal include:

• conjunctival hemorrhage 
• increased intraocular pressure 
• blurred vision
• neovascular AMD

Serious side effects of Avacincaptad Pegol Intravitreal include:

• ocular and periocular infections
• increased elevated intraocular inflammation 
• endophthalmitis and retinal detachments
• neovascular AMD
• increase in intraocular pressure

Rare side effects of Avacincaptad Pegol Intravitreal include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors.
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights.
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, light-headedness, or passing out

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Injectable solution for intravitreal use

• 20 mg/mL single-dose vial

Geographic Atrophy

Adult dosage

• 2 mg (0.1 mL) by intravitreal injection to each affected eye once monthly (approximately 28 ± 7 days) for up to 12 months

Dosage Considerations – Should be Given as Follows:

• See "Dosages"

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Avacincaptad Pegol Intravitreal has no noted severe interactions with any other drugs.
• Avacincaptad Pegol Intravitreal has no noted serious interactions with any other drugs.
• Avacincaptad Pegol Intravitreal has no noted moderate interactions with any other drugs.
• Avacincaptad Pegol Intravitreal has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• Ocular or periocular infections
• Active intraocular inflammation

Effects of drug abuse

• None

Short-Term Effects

• See "What Are Side Effects Associated with Using Avacincaptad Pegol Intravitreal?"

Long-Term Effects

• See "What Are Side Effects Associated with Using Avacincaptad Pegol Intravitreal?"

Cautions

• Use may be associated with increased rates of neovascular (wet) AMD or choroidal neovascularization; monitor for signs of neovascular AMD
• Transient increases in intraocular pressure observed after administration; monitor perfusion of optic nerve head following injection and manage accordingly
• Endophthalmitis and retinal detachments
  • Intravitreal injection may be associated with endophthalmitis and retinal detachments
  • Use proper aseptic technique during administration to minimize the risk of endophthalmitis
  • Instruct patients to promptly report any symptoms suggestive of endophthalmitis or retinal detachment and manage appropriately

Pregnancy and Lactation

• There are no adequate and well-controlled studies of use in pregnant women
• Lactation
  • There is no information regarding the presence of avacincaptad pegol in human milk or its effects on breastfed infants or milk production